Therapy Areas: Oncology
AbbVie's VENCLEXTA (venetoclax) and acalabrutinib combination receives US FDA approval to treat CLL
23 February 2026 - US pharmaceutical company AbbVie (NYSE:ABBV) announced on Friday that the US Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for the com...
CStone Pharmaceuticals' sugemalimab granted new indication by UK MHRA
23 February 2026 - Chinese biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) announced on Sunday that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a new ind...
FDA accepts Genentech application for giredestrant combination in ESR1-mutated advanced breast cancer
20 February 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that the US Food and Drug Administration (FDA) has accepted its New D...
EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer
19 February 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Thursday that the European Medicines Agency has validated a Type II variation application for Enhertu (tras...
IBA and Shreeji sign agreement to deploy four cyclotrons for PET radiopharmaceuticals in India
19 February 2026 - Particle accelerator technology company Ion Beam Applications S.A. (IBA) (Euronext Brussels:IBAB) on Thursday announced a new agreement with Shreeji Imaging and Diagnostic Centre Pv...
AVEO Oncology completes first interim analysis in global Phase 3 FIERCE-HN study
19 February 2026 - US-based AVEO Oncology, an LG Chem (KRX:051910) company, announced on Wednesday that the 20mg/kg dose of ficlatuzumab has been chosen for the combination arm of the Phase 3 registra...